Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease|
- MRI to show differences between bevacizumab responses [ Time Frame: 1 month ] [ Designated as safety issue: No ]The MRI parameters will help show the differences between bevacizumab-responsive and bevacizumab non-responsive recurrent glioblastoma
- Progression Free Survival at 3 months [ Time Frame: 3 months ] [ Designated as safety issue: No ]The progression of the subject's disease will be evaluated at 3 months.
|Study Start Date:||July 2012|
|Study Completion Date:||September 2014|
|Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
|glioblastoma patients on bevacizumab||
Radiation: Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. Bevacizumab is a drug that your doctor believes is the best treatment option available to subjects at this time for this type of tumor. Bevacizumab affects the growth of blood vessels by tumors such as glioblastoma, thus effectively starving the tumor of oxygen and food.
Magnetic Resonance Imaging (MRI) is a test done by a machine in the radiology department that takes pictures of your body using special magnets, rather than X-rays. With a new MRI scan technique the investigators can take very, very detailed images of the vessel and tumor structure. This project will allow us to compare the images of vessel and tumor structure to the effectiveness of Bevacizumab as a treatment option. With this project the investigators will hopefully develop an accurate way to predict whether or not Bevacizumab will be an effective treatment option for patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01604590
|United States, South Carolina|
|Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Principal Investigator:||Pierre Giglio, MD||Medical University of South Carolina|